|
Post by runner on Aug 28, 2024 10:55:37 GMT -5
Three bounces off $ 6.15 so far. Will be interesting to see when this goes IF MNKD can manage to break through that price. Just bounced up to $6.22.
|
|
|
Post by peppy on Aug 28, 2024 10:59:45 GMT -5
There are also 3 conference participation early in the next 2 weeks.... may be some good staff can out-come as well. May be some other good target price raising, as well Hopefully I love this set up. Triangle breaks. It is said, all the longs and shorts fighting.... creates pressure. then the pressure breaks.... price goes in that direction. MNKD has been a three year pressure cooker since the UTHR deal. Ever work a pressure cooker with the weight on top. The weight starts to jiggle and the steam starts coming out...... Under pressure.
|
|
|
Post by parrerob on Aug 28, 2024 11:08:47 GMT -5
I would like that the Oppenheimer raise on share price target and "analyst consensus" of STRONG BUY would be the reason for the sharp increase, but I would frankly be as surprised by that as I would by technical analysis being the reason. My suspicious nature wonders if there is news that hasn't yet broken. I'm pleased that UTHR is part of the run up, because I've become increasingly concerned Boehringer Ingelheim (makers of Jardiance and Ofev) will consider a buyout of MannKind if the nintedanib DPI Phase 1 trial goes well (which I assume it should). I'm not against a buyout, but would be very sorry that it would happen now while the share price is less than $10 and where the premium on a BO would be about $12 per share. I think a well-negotiated partnership for Ofev DPI could yield $1 to $2 EPS by 2030. Therefore I would much prefer technicals or analyst opinions (and fundamentals) be the reason for the increase in share price and so it comforts me UTHR is also enjoying a similar run because it implies there could be news other than a buyout, but perhaps still not publicly disclosed. 12$ ? Remember MC recently spoke about a company with a value of 1,4 B$ then after a good trial was sold for 8 B$ Dreaming ? Coincidence ? Parable ? May be..... MNKD With only Afrezza was evaluated 4B$ (Before approval) - Could be value of nintedanib for Boehringer Ingelheim to continue and increase their business ? Tyvaso DPI evaluated minimum 1,5 B$ (Sagard)... minimum Afrezza now evaluated ? 1 B$ ? (Considering actual situations and studies on going) Clofazimine ? Pipeline ? And don't forget V-Go I like days like this one..... Feel free to dream !
|
|
|
Post by ktim on Aug 28, 2024 11:10:43 GMT -5
Hmmm, prcgorman2 ... everyone used to dream about a buyout... now we're waking up from nightmares about buyouts? Think it's rather premature to do any dreaming or worrying. parrerob, was that buyout parable or parabolic? And was it a Phase 1 trial?
|
|
|
Post by prcgorman2 on Aug 28, 2024 11:14:12 GMT -5
Interesting that Yahoo! shows CHWY (Chewy) as the Top Gainer today and MNKD's gain has (or had) been a bigger percentage than CHWY's. MNKD doesn't even appear in their list.
|
|
|
Post by casualinvestor on Aug 28, 2024 11:31:35 GMT -5
Yahoo also doesn't show the Oppenheimer upgrade as news when you look at the MNKD quote page finance.yahoo.com/quote/MNKD/Doesn't show for UTHR either
|
|
|
Post by prcgorman2 on Aug 28, 2024 12:09:52 GMT -5
Hmmm, prcgorman2 ... everyone used to dream about a buyout... now we're waking up from nightmares about buyouts? Think it's rather premature to do any dreaming or worrying. parrerob , was that buyout parable or parabolic? And was it a Phase 1 trial? Too early to worry? My experience with corporate timetables is something along the lines of "If you want to do something substantial in January 2025 (e.g., acquisition), you need to have been working on it in January of 2024, or maybe 2023."
Seriously, if Boehringer Ingelheim needs to be able to usefully react to a good readout of the MannKind nintedanib DPI Phase 1 trial in 4Q 2024, they need to be thinking about it now (or sooner). If they're thinking about it, I don't think it's too early for me to be thinking about it.
BI may already be in conversation with MannKind about the possibility of partnership. If they want to execute on a partnership, they'll need to come up with a bunch of cash, and lawyers. Same for a buyout. Now, is it an urgent issue for BI? Perhaps not. But is it an important issue? How could it not be? Ofev is their 2nd largest selling drug behind Jardiance. It's a key core product.
|
|
|
Post by radgray68 on Aug 28, 2024 12:32:36 GMT -5
BI is in both lung disease and diabetes. Their portfolio dovetails with ours better than most. The better question is? Why wouldn’t BI buy us? Or, at least partner?
|
|
|
Post by ktim on Aug 28, 2024 12:43:05 GMT -5
Why not is one of the more succinct arguments for buyout we've had here over the years. Well, I guess this time the buyout is as good as done
|
|
|
Post by peppy on Aug 28, 2024 12:45:30 GMT -5
BI is in both lung disease and diabetes. Their portfolio dovetails with ours better than most. The better question is? Why wouldn’t BI buy us? Or, at least partner? radgray68 or team; brain death over here. What is BI?
|
|
|
Post by liane on Aug 28, 2024 12:59:23 GMT -5
BI is in both lung disease and diabetes. Their portfolio dovetails with ours better than most. The better question is? Why wouldn’t BI buy us? Or, at least partner? radgray68 or team; brain death over here. What is BI? Boehringer Ingelheim
|
|
|
Post by mytakeonit on Aug 28, 2024 13:15:10 GMT -5
Sorry ... but my crystal balls says no buy out in the near future. Did everybody buy all the cheap shares they could We're headed to $10. But, that's mytakeonit
|
|
|
Post by cretin11 on Aug 28, 2024 13:23:15 GMT -5
Wow, they call MTOI’s crystal ball the “opposite crystal ball” which means the odds of an imminent buyout just went way up!
(I kid, I kid…)
|
|
|
Post by uvula on Aug 28, 2024 13:27:23 GMT -5
I hope there is no buyout. I would feel like an idiot owning stock in a company I can't spell.
|
|
|
Post by cretin11 on Aug 28, 2024 13:29:58 GMT -5
I hope there is no buyout. I would feel like an idiot owning stock in a company I can't spell. Unless an all cash buyout then no worries there! (Or alternatively just immediately sell your BI shares and lock in the win, never needing to learn how to spell it)
|
|